InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report report published on Friday. The brokerage issued a sell rating on the stock.

Separately, Lake Street Capital started coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price on the stock.

InspireMD Stock Up 2.8 %

NYSE:NSPR opened at $2.94 on Friday. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42. The company has a fifty day simple moving average of $2.79 and a two-hundred day simple moving average of $2.73. The company has a market cap of $76.68 million, a price-to-earnings ratio of -3.92 and a beta of 1.00.

InspireMD (NYSE:NSPR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter in the prior year, the business earned ($0.15) EPS. On average, analysts expect that InspireMD will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Affiance Financial LLC lifted its stake in InspireMD by 2.9% during the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new stake in shares of InspireMD during the 3rd quarter worth approximately $279,000. Northern Trust Corp boosted its holdings in shares of InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after buying an additional 24,452 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its position in shares of InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after buying an additional 18,233 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in InspireMD during the 4th quarter worth $27,000. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.